Transvaginal Mesh

On 30 November 2017, the Therapeutic Goods Administration removed a number of mesh products whose sole use is the treatment of pelvic organ prolapse via transvaginal implantation from the Australian Register of Therapeutic Goods. The TGA has established a Transvaginal (urogynaecological) surgical mesh hub webpage for consumers.

There has been a great deal of interest and comment recently about the use of mesh as part of the surgical treatment of vaginal prolapse and urinary incontinence. A Senate Inquiry into the Number of women in Australia who have had transvaginal mesh implants and related matters was held and the report on its findings was released on 28 March 2018. ACT Health has incorporated the findings and recommendations of this report into our response.

On 30 November 2017, the Therapeutic Goods Administration removed a number of mesh products whose sole use is the treatment of pelvic organ prolapse via transvaginal implantation from the Australian Register of Therapeutic Goods. The TGA has established a Transvaginal (urogynaecological) surgical mesh hub webpage for consumers.

The Australian Commission on Safety and Quality in Health Care (the Commission) is working to develop guidance documents for patients, clinicians and for health service organisations. More information can be found here.

ACT Health has directly contacted all women that have been identified as having undergone surgery or treatment of this type at Canberra Hospital and Health Services, within the past 10 years, to notify them of the issue and the options available to them if they are concerned.

If you have undergone surgery or treatment of this type and have any concerns or questions, please contact your GP or gynaecologist directly, or call the dedicated Mesh telephone service at ACT Health on 02 5124 7474 or email meshreview@act.gov.au for information and support.

Page last updated on: 26 Oct 2018